ArticleJAMA oncology2022
Rates of Guideline-Concordant Surgery and Adjuvant Chemotherapy Among Patients With Early-Stage Lung Cancer in the US ALCHEMIST Study (Alliance A151216).
Article in JAMA oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02194738 (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial), which is not on this map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Who cites it
32 citing papers in PubMed, 50 citations in OpenAlex.
- Trial
- Prognostic factors and survival prediction for patients with metastatic lung adenocarcinoma: A population-based study.Medicine · 2022Trial
- Female underrepresentation and adverse events reporting biases in lung cancer clinical trials: a systematic review and meta-analysis.Journal of the National Cancer Center · 2026Article
- Review
- Adherence to Postoperative Survivorship Quality Metrics in Early-Stage Non-Small Cell Lung Cancer.The Annals of thoracic surgery · 2026Article
- State of the art of perioperative assessment in early non-small-cell lung cancer in Poland in the emerging era of perioperative protocols.Therapeutic advances in medical oncology · 2026Article
- Clinical stage II non-small cell lung cancer: can we "just give adjuvant therapy"?Journal of thoracic disease · 2025Article
- Microfluidic lung cancer models: Bridging clinical treatment strategies and tumor microenvironment recapitulation.APL bioengineering · 2025Review
- Real-World Adoption of Adjuvant Therapies for Resected Stage IB-III Non-Small-Cell Lung Cancer.Cancers · 2025Article
- Article
- Combining computed tomography features of left atrial epicardial and pericoronary adipose tissue with the triglyceride-glucose index to predict the recurrence of atrial fibrillation after radiofrequency catheter ablation: a machine learning study.Quantitative imaging in medicine and surgery · 2024Article
- Lymphatic vascular invasion: Diagnostic variability and overall survival impact on patients undergoing surgical resection.JTCVS open · 2024Article
- A retrospective analysis of treatment patterns, overall survival, and real-world disease-free survival in early-stage non-small cell lung cancer following complete resection.BMC pulmonary medicine · 2024Article
- Review
- Clinical and economic outcomes associated with lymph node examination status in early-stage non-small cell lung cancer: a real-world US study using the SEER-Medicare linked database.Translational cancer research · 2024Article
- Challenges and controversies in resectable non-small cell lung cancer: a clinician's perspective.The Lancet regional health. Europe · 2024Review
- Two Interventions on Pathologic Nodal Staging in a Population-Based Lung Cancer Resection Cohort.The Annals of thoracic surgery · 2024Article
- Avoided recurrences and costs with adjuvant atezolizumab for patients with early non-small cell lung cancer in Europe.Immunotherapy · 2024Article
- Is underutilization of adjuvant therapy in resected non-small-cell lung cancer associated with socioeconomic disparities?European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery · 2023Article
- Immune-checkpoint inhibition for resectable non-small-cell lung cancer - opportunities and challenges.Nature reviews. Clinical oncology · 2023Review
Corrections and comments
- Commented on by
Authors and funding
17 authors at 10 institutions in 1 country.
Funding
Abstract
Importance: Standard treatment for resectable non-small cell lung cancer (NSCLC) includes anatomic resection with adequate lymph node dissection and adjuvant chemotherapy for appropriate patients. Historically, many patients with early-stage NSCLC have not received such treatment, which may affect the interpretation of the results of adjuvant therapy trials. Objective: To ascertain patterns of guideline-concordant treatment among patients enrolled in a US-wide screening protocol for adjuvant treatment trials for resected NSCLC. Design, Setting, and Participants: This retrospective cohort study included 2833 patients with stage IB to IIIA NSCLC (per American Joint Committee on Cancer 7th edition criteria) who enrolled in the Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST) screening study (Alliance for Clinical Trials in Oncology A151216) from August 18, 2014, to April 1, 2019, and who did not enroll in a therapeutic adjuvant clinical trial; patients had tumors of at least 4 cm and/or with positive lymph nodes. Statistical analysis was conducted from June 1, 2020, through October 1, 2021. Exposures: Care patterns were ascertained overall and by sociodemographic and clinical factors, including age, sex, race and ethnicity, educational level, marital status, geography, histologic characteristics, stage, genomic variant status, smoking history, and comorbidities. Main Outcomes and Measures: Five outcomes are reported: whether patients (1) had anatomic surgical resection, (2) had adequate lymph node dissection (≥1 N1 nodal station plus ≥3 N2 nodal stations), (3) received any adjuvant chemotherapy, (4) received any cisplatin-based adjuvant chemotherapy, and (5) received at least 4 cycles of adjuvant chemotherapy. Results: Of the 2833 patients (1505 women [53%]; mean [SD] age, 66.5 [9.2] years) included in this analysis, 2697 (95%) had anatomic surgical resection, 1513 (53%) had adequate lymph node dissection, 1617 (57%) received any adjuvant chemotherapy, 1237 (44%) received at least 4 cycles of adjuvant platinum-based chemotherapy, and 965 (34%) received any cisplatin-based adjuvant chemotherapy. Rates were similar across race and ethnicity. Conclusions and Relevance: This cohort study found that among participants in a screening protocol for adjuvant clinical trials for resected early-stage NSCLC, just 53% underwent adequate lymph node dissection, and 57% received adjuvant chemotherapy, despite indications for such treatment. These results may affect the interpretation of adjuvant trials. Efforts are needed to optimize the use of proven therapies for early-stage NSCLC. Trial Registration: ClinicalTrials.gov Identifier: NCT02194738.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.